KR970707101A - Substituted benzylamine derivatives; A new class of neuropeptide Y1 specific ligands (CERTAIN SUBSTITUTED BENZYLAMINE DERIVATIVES; A NEW CLASS OF NEUROPEPTIDE Y1 SPECIFIC LIGANDS) - Google Patents

Substituted benzylamine derivatives; A new class of neuropeptide Y1 specific ligands (CERTAIN SUBSTITUTED BENZYLAMINE DERIVATIVES; A NEW CLASS OF NEUROPEPTIDE Y1 SPECIFIC LIGANDS)

Info

Publication number
KR970707101A
KR970707101A KR1019970702989A KR19970702989A KR970707101A KR 970707101 A KR970707101 A KR 970707101A KR 1019970702989 A KR1019970702989 A KR 1019970702989A KR 19970702989 A KR19970702989 A KR 19970702989A KR 970707101 A KR970707101 A KR 970707101A
Authority
KR
South Korea
Prior art keywords
compound according
phenylpiperazin
straight
cyclohexane
carbon atoms
Prior art date
Application number
KR1019970702989A
Other languages
Korean (ko)
Inventor
존 엠 피터슨
찰스 에이 블럼
구올린 카이
알란 허치슨
Original Assignee
스피겔 알렌 제이
화이자 인코포레이티드
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 스피겔 알렌 제이, 화이자 인코포레이티드 filed Critical 스피겔 알렌 제이
Publication of KR970707101A publication Critical patent/KR970707101A/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D213/72—Nitrogen atoms
    • C07D213/74—Amino or imino radicals substituted by hydrocarbon or substituted hydrocarbon radicals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/24—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with substituted hydrocarbon radicals attached to ring carbon atoms
    • C07D213/36—Radicals substituted by singly-bound nitrogen atoms
    • C07D213/38—Radicals substituted by singly-bound nitrogen atoms having only hydrogen or hydrocarbon radicals attached to the substituent nitrogen atom
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/02—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
    • C07D239/24—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
    • C07D239/28—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
    • C07D239/32—One oxygen, sulfur or nitrogen atom
    • C07D239/42—One nitrogen atom
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D295/00—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms
    • C07D295/02—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms containing only hydrogen and carbon atoms in addition to the ring hetero elements
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D295/00—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms
    • C07D295/02—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms containing only hydrogen and carbon atoms in addition to the ring hetero elements
    • C07D295/027—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms containing only hydrogen and carbon atoms in addition to the ring hetero elements containing only one hetero ring
    • C07D295/033—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms containing only hydrogen and carbon atoms in addition to the ring hetero elements containing only one hetero ring with the ring nitrogen atoms directly attached to carbocyclic rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D295/00—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms
    • C07D295/04—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms
    • C07D295/08—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms substituted by singly bound oxygen or sulfur atoms
    • C07D295/096—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms substituted by singly bound oxygen or sulfur atoms with the ring nitrogen atoms and the oxygen or sulfur atoms separated by carbocyclic rings or by carbon chains interrupted by carbocyclic rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D309/00—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only ring hetero atom, not condensed with other rings
    • C07D309/02—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only ring hetero atom, not condensed with other rings having no double bonds between ring members or between ring members and non-ring members
    • C07D309/08—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only ring hetero atom, not condensed with other rings having no double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D309/14—Nitrogen atoms not forming part of a nitro radical
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D317/00—Heterocyclic compounds containing five-membered rings having two oxygen atoms as the only ring hetero atoms
    • C07D317/08—Heterocyclic compounds containing five-membered rings having two oxygen atoms as the only ring hetero atoms having the hetero atoms in positions 1 and 3
    • C07D317/44—Heterocyclic compounds containing five-membered rings having two oxygen atoms as the only ring hetero atoms having the hetero atoms in positions 1 and 3 ortho- or peri-condensed with carbocyclic rings or ring systems
    • C07D317/46—Heterocyclic compounds containing five-membered rings having two oxygen atoms as the only ring hetero atoms having the hetero atoms in positions 1 and 3 ortho- or peri-condensed with carbocyclic rings or ring systems condensed with one six-membered ring
    • C07D317/48—Methylenedioxybenzenes or hydrogenated methylenedioxybenzenes, unsubstituted on the hetero ring
    • C07D317/50—Methylenedioxybenzenes or hydrogenated methylenedioxybenzenes, unsubstituted on the hetero ring with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to atoms of the carbocyclic ring
    • C07D317/58—Radicals substituted by nitrogen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D335/00—Heterocyclic compounds containing six-membered rings having one sulfur atom as the only ring hetero atom
    • C07D335/02—Heterocyclic compounds containing six-membered rings having one sulfur atom as the only ring hetero atom not condensed with other rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C2601/00—Systems containing only non-condensed rings
    • C07C2601/12—Systems containing only non-condensed rings with a six-membered ring
    • C07C2601/14—The ring being saturated

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Hematology (AREA)
  • Diabetes (AREA)
  • Child & Adolescent Psychology (AREA)
  • Obesity (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Pyridine Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Abstract

본 발명은 인간의 신경펩타이드 Y1 수용체에 대한 결합력에 기인하여 비만 및 병적 기아 등의 섭식 장애, 및 본질적인 고혈압 및 울혈성 심부전 등의 심혈관계 질환을 진단하고 치료하는데 유용한 화학식(Ⅰ)의 화합물 및 약학적으로 허용가능한 이의 염을 포함한다:The present invention relates to compounds of formula (I) useful for diagnosing and treating cardiovascular diseases, such as eating disorders such as obesity and pathological starvation, and intrinsic hypertension and congestive heart failure, due to binding capacity to human neuropeptide Y1 receptor Or a pharmaceutically acceptable salt thereof:

상기 식에서 W, X, Y, A 및 T는 유기 또는 무기 치환체이고, n은 1, 2 또는 3이고, m은 2, 3 또는 4이고, R1내지 R4는 수소 또는 유기 치환체이고, B는 질소, 탄소, 황 또는 산소이다.Wherein n is 1, 2 or 3, m is 2, 3 or 4, R 1 to R 4 are hydrogen or an organic substituent, and B is Nitrogen, carbon, sulfur or oxygen.

Description

치환된 벤질아민 유도체; 신규한 부류의 신경펩타이드 Y1 특이적 리간드(CERTAIN SUBSTITUTED BENZYLAMINE DERIVATIVES; A NEW CLASS OF NEUROPEPTIDE Y1 SPECIFIC LIGANDS)Substituted benzylamine derivatives; A new class of neuropeptide Y1 specific ligands (CERTAIN SUBSTITUTED BENZYLAMINE DERIVATIVES; A NEW CLASS OF NEUROPEPTIDE Y1 SPECIFIC LIGANDS)

본 내용은 요부공개 건이므로 전문내용을 수록하지 않았음Since this is a trivial issue, I did not include the contents of the text.

Claims (28)

화학식(Ⅰ)의 화합물 또는 약학적으로 허용가능한 이의 염:A compound of formula (I) or a pharmaceutically acceptable salt thereof: 상기 식에서, Ar은 페닐, 2-, 3- 또는 4-피리딜, 2- 또는 3-티에닐, 2-, 4- 또는 5-피리미딜이고, 이들 각각은 임의로 할로겐, 하이드록시, 또는 탄소수 1 내지 6의 직쇄 또는 측쇄의 저급 알킬로 단치환 또는 이치환되고; B는 황, 산소, N(R5), 또는 C(R5)(R6)이고; n은 1, 2 또는 3이고; m은 2, 3 또는 4이고; W, XY 및 T는 동일하거나 상이하고, 수소, 할로겐, 하이드록시, 탄소수 1 내지 6의 직쇄 또는 측쇄의 저급 알킬, 또는 탄소수 1 내지 6의 직쇄는 측쇄의 저급 알콕시이고; R1및 R2는 동일하거나 상이하고, 수소, 또는 탄소수 1 내지 6의 직쇄 또는 측쇄의 저급 알킬이고; R3및 R4는 동일하거나 상이하고, 수소, 탄소수 1 내지 6의 직쇄 또는 측쇄의 저급 알킬, 또는 탄소수 1 내지 6의 직쇄 또는 측쇄의 저급 알콕시이고; R5는 탄소수 1 내지 6의 직쇄 또는 측쇄의 저급 알킬, 페닐, 2-, 3- 또는 4-피리딜 또는 탄소수 1 내지 6의 직쇄 또는 측쇄의 저급 알킬로 치환된 페닐, 2-, 3- 또는 4-피리딜이고; A 및 R6은 동일하거나 상이하고, 수소, 하이드록실, 아미노, 탄소수 1 내지 6의 직쇄 또는 측쇄의 저급 알킬, 탄소수 1 내지 6의 직쇄 또는 측쇄의 저급 알콕시, 페닐, 2-, 3- 또는 4-피리딜, 페녹시, 2-, 3- 또는 4-피리딜옥시, 또는 -(CH2)p-A'-(CH2)qB'이고, 이때 p는 0 내지 5이고, q는 1 내지 5이고, A'는 직접 결합, 산소 또는 황이고, B'는 수소, 탄소수 1 내지 6의 직쇄 또는 측쇄의 저급 알킬, 탄소수 1 내지 6의 직쇄 또는 측쇄의 저급 알콕시, 페닐, 2-, 3- 또는 4-피리딜, 페녹시, 2-, 3- 또는 4-피리딜옥시, 카복실, 카보알콕시, 카복스아미도, 모노 또는 디알킬카복스아미도, 아미노, 또는 모노 또는 디알킬아미노이다.Wherein Ar is phenyl, 2-, 3- or 4-pyridyl, 2- or 3-thienyl, 2-, 4- or 5-pyrimidyl, each of which is optionally substituted with halogen, ≪ / RTI > to 6, linear or branched, lower alkyl; B is sulfur, oxygen, N (R 5), or C (R 5) (R 6 ) , and; n is 1, 2 or 3; m is 2, 3 or 4; W, XY and T are the same or different and are hydrogen, halogen, hydroxy, straight or branched chain lower alkyl of 1 to 6 carbon atoms, or straight chain of 1 to 6 carbon atoms are lower alkoxy of side chain; R 1 and R 2 are the same or different and each is hydrogen or a straight or branched chain lower alkyl having 1 to 6 carbon atoms; R 3 and R 4 are the same or different and each is hydrogen, a straight or branched chain lower alkyl having 1 to 6 carbon atoms, or a straight or branched lower alkoxy having 1 to 6 carbon atoms; R 5 is a straight or branched chain lower alkyl having 1 to 6 carbon atoms, phenyl, 2-, 3- or 4-pyridyl, phenyl substituted with straight or branched chain lower alkyl having 1 to 6 carbon atoms, 2-, 4-pyridyl; A and R 6 are the same or different and are hydrogen, hydroxyl, amino, straight or branched chain alkyl of 1 to 6 carbon atoms, straight or branched chain lower alkoxy of 1 to 6 carbon atoms, phenyl, 2-, -pyridyl, phenoxy, 2-, 3- or 4-pyridyloxy, or - (CH 2) p -A ' - (CH 2) q B' , and wherein p is from 0 to 5, q is 1, And A 'is a direct bond, oxygen or sulfur, B' is hydrogen, straight or branched chain alkyl of 1 to 6 carbon atoms, straight or branched chain lower alkoxy of 1 to 6 carbon atoms, phenyl, 2- or 3 - or 4-pyridyl, phenoxy, 2-, 3- or 4-pyridyloxy, carboxyl, carboalkoxy, carboxamido, mono or dialkylcarboxamido, amino or mono or dialkylamino . 화학식(ⅠA)의 화합물:A compound of formula (IA): 상기 식에서, Ar은 페닐, 2-, 3- 또는 4-피리딜, 2- 또는 3-티에닐, 2-, 4- 또는 5-피리미딜이고, 이들 각각은 임의로 할로겐, 하이드록시, 또는 탄소수 1 내지 6의 직쇄 또는 측쇄의 저급 알킬에 의해 단치환 또는 이치환되고; A, W, X, Y 및 T는 동일하거나 상이하고, 수소, 할로겐, 하이드록시, 탄소수 1 내지 6 직쇄 또는 측쇄의 저급 알킬, 또는 탄소수 1 내지 6의 직쇄 또는 측쇄의 저급 알콕시이고; R1 및 R2는 동일하거나 상이하고, 수소, 또는 탄소수 1 내지 6의 직쇄 또는 측쇄의 저급 알킬이고; R3 및 R4는 동일하거나 상이하고, 수소 탄소수 1 내지 6의 직쇄 또는 측쇄의 저급 알킬, 또는 탄소수 1 내지 6의 직쇄 또는 측쇄의 저급 알콕시이고; R9는 수소, 탄소수 1 내지 6의 직쇄 또는 측쇄의 저급 알킬, 또는 페닐이다.Wherein Ar is phenyl, 2-, 3- or 4-pyridyl, 2- or 3-thienyl, 2-, 4- or 5-pyrimidyl, each of which is optionally substituted with halogen, ≪ / RTI > to 6, straight or branched chain lower alkyl; A, W, X, Y and T are the same or different and are hydrogen, halogen, hydroxy, lower alkyl of 1 to 6 carbon atoms straight or branched, or straight or branched chain lower alkoxy of 1 to 6 carbon atoms; R1 and R2 are the same or different and are hydrogen or a straight or branched chain lower alkyl having 1 to 6 carbon atoms; R3 and R4 are the same or different and are a straight chain or branched chain lower alkyl having 1 to 6 hydrogen atoms or a straight chain or branched lower alkoxy having 1 to 6 carbon atoms; R 9 is hydrogen, straight or branched chain lower alkyl of 1 to 6 carbon atoms, or phenyl. 제2항에 있어서, A가 저급 알콕시인 화합물.3. A compound according to claim 2, wherein A is lower alkoxy. 제1항에 있어서, 1-페닐-1-(4-페닐피페라진-1-일)-사이클로헥산인 화합물.2. The compound according to claim 1, which is 1-phenyl-1- (4-phenylpiperazin-1-yl) -cyclohexane. 제1항에 있어서, 1-(3-메톡시페닐)-1-(4-페닐피페라진-1-일)-사이클로헥산인 화합물.The compound according to claim 1, which is 1- (3-methoxyphenyl) -1- (4-phenylpiperazin-1-yl) -cyclohexane. 제1항에 있어서, 1-(3-메톡시페닐)-1-[4-(2-피리미디닐)-피페라진-1-일]-사이클로헥산인 화합물.The compound according to claim 1, which is 1- (3-methoxyphenyl) -1- [4- (2-pyrimidinyl) -piperazin-1-yl] -cyclohexane. 제1항에 있어서, 1-(3-메톡시페닐)-1-[4-(2-피리미디닐)-피페라진-1-일]-사이클로헥산인 화합물.The compound according to claim 1, which is 1- (3-methoxyphenyl) -1- [4- (2-pyrimidinyl) -piperazin-1-yl] -cyclohexane. 제1항에 있어서, 1-(3-메톡시페닐)-1-[4-(2-플루오로페닐)-피페라진-1-일]-사이클로헥산인 화합물.The compound according to claim 1, which is 1- (3-methoxyphenyl) -1- [4- (2-fluorophenyl) -piperazin-1-yl] -cyclohexane. 제1항에 있어서, 1-(3-메톡시페닐)-1-[4-(4-플루오로페닐)-피페라진-1-일]-사이클로헥산인 화합물.The compound according to claim 1, which is 1- (3-methoxyphenyl) -1- [4- (4-fluorophenyl) -piperazin-1-yl] -cyclohexane. 제1항에 있어서, 1-(3-하이드록시페닐)-1-(4-페닐피페라진-1-일]-사이클로헥산인 화합물.2. The compound according to claim 1, which is 1- (3-hydroxyphenyl) -1- (4-phenylpiperazin-1-yl) -cyclohexane. 제1항에 있어서, 1-(3,5-디메톡시페닐)-1-(4-페닐피페라진-1-일]-사이클로헥산인 화합물.The compound according to claim 1, which is 1- (3,5-dimethoxyphenyl) -1- (4-phenylpiperazin-1-yl) -cyclohexane. 제1항에 있어서, 1-(3-에톡시페닐)-1-(4-페닐피페라진-1-일)-사이클로헥산인 화합물.The compound according to claim 1, which is 1- (3-ethoxyphenyl) -1- (4-phenylpiperazin-1-yl) -cyclohexane. 제1항에 있어서, 1-(3-메톡시페닐)-1-(4-페닐피페라진-1-일)-4-페닐-사이클로헥산의 부분입체이성체 둘다인 화합물.The compound according to claim 1, which is both diastereomers of 1- (3-methoxyphenyl) -1- (4-phenylpiperazin-1-yl) -4-phenyl-cyclohexane. 제1항에 있어서, 1-(3-n-부톡시페닐)-1-(4-페닐피페라진-1-일)-사이클로헥산인 화합물.The compound according to claim 1, which is 1- (3-n-butoxyphenyl) -1- (4-phenylpiperazin-1-yl) -cyclohexane. 제1항에 있어서, 1-(3-메톡시페닐)-1-(4-페닐피페라진-1-일)-4-메틸-사이클로헥산의 부분입체이성체 둘다인 화합물.4. The compound according to claim 1 which is both diastereomers of 1- (3-methoxyphenyl) -1- (4-phenylpiperazin-1-yl) -4-methyl-cyclohexane. 제1항에 있어서, 1-(4-메톡시페닐)-1-(4-페닐피페라진-1-일)-사이클록헥산인 화합물.The compound according to claim 1, which is 1- (4-methoxyphenyl) -1- (4-phenylpiperazin-1-yl) -cyclohexane. 제1항에 있어서, 1-(2-메톡시페닐)-1-(4-페닐피페라진-1-일)-사이클록헥산인 화합물.The compound according to claim 1, which is 1- (2-methoxyphenyl) -1- (4-phenylpiperazin-1-yl) -cyclohexane. 제1항에 있어서, 1-(3,4-메텐디옥시페닐)-1-(4-페닐피페라진-1-일)-사이클록헥산인 화합물.The compound according to claim 1, which is 1- (3,4-methylenedioxyphenyl) -1- (4-phenylpiperazin-1-yl) -cyclohexane. 제1항에 있어서, 1-(3-에톡시페닐)-1-(4-페닐피페라진-1-일)-4-메틸-사이클록헥산의 부분입체이성체 둘다인 화합물.The compound according to claim 1, which is both diastereomers of 1- (3-ethoxyphenyl) -1- (4-phenylpiperazin-1-yl) -4-methyl-cyclic hexane. 제1항에 있어서, 1-(3-에톡시페닐)-1-(4-페닐피페라진-1-일)-4-에틸-사이클록헥산의 부분입체이성체 둘다인 화합물.The compound according to claim 1, which is both diastereomers of 1- (3-ethoxyphenyl) -1- (4-phenylpiperazin-1-yl) -4-ethyl-cyclic hexane. 제1항에 있어서, 1-(3-이소프로폭시페닐)-1-(4-페닐피페라진-1-일)-4-메틸-사이클록헥산의 부분입체이성체 둘다인 화합물.The compound according to claim 1, which is both diastereomers of 1- (3-isopropoxyphenyl) -1- (4-phenylpiperazin-1-yl) -4-methyl-cyclohexane. 제1항에 있어서, 1-(3-메톡시페닐)-1-(4-페닐피페라진-1-일)-3-메틸-사이클록헥산의 부분입체이성체 둘다인 화합물.The compound according to claim 1, which is both diastereomers of 1- (3-methoxyphenyl) -1- (4-phenylpiperazin-1-yl) -3-methylcyclohexane. 제1항에 있어서, 1-(3-벤질옥시페닐)-1-(4-페닐피페라진-1-일)-사이클록헥산 디하이드로클로라이드인 화합물.The compound according to claim 1, which is 1- (3-benzyloxyphenyl) -1- (4-phenylpiperazin-1-yl) -cyclohexane dihydrochloride. 제1항에 있어서, 4-(3-에톡시페닐)-4-(4-페닐피페라진-1-일)-테트라하이드로피란인 화합물.The compound according to claim 1, which is 4- (3-ethoxyphenyl) -4- (4-phenylpiperazin-1-yl) -tetrahydropyran. 제1항에 있어서, 4-(3-에톡시페닐)-4-(4-페닐피페라진-1-일)-테라하이드로티오피란인 화합물.The compound according to claim 1, which is 4- (3-ethoxyphenyl) -4- (4-phenylpiperazin-1-yl) -tetrahydrothiopyran. 제1항에 있어서, 1-(3-메톡시메톡시페닐)-1-(4-페닐피페라진-1-일)-4-메틸-사이클록헥산의 부분입체 이상체 둘다인 화합물.The compound according to claim 1, which is both a diastereomer of 1- (3-methoxymethoxyphenyl) -1- (4-phenylpiperazin-1-yl) -4-methylcyclohexane. 제1항에 있어서, 1-(3-에톡시메톡시페닐)-1-(4-페닐피페라진-1-일)-4-메틸-사이클록헥산의 부분입체이성체 둘다인 화합물.The compound according to claim 1, which is both diastereomers of 1- (3-ethoxymethoxyphenyl) -1- (4-phenylpiperazin-1-yl) -4-methyl-cyclic hexane. 제1항에 있어서, 1-(3-에톡시페닐)-1-(4-페닐피페라진-1-일)-4-메톡시-사이클록헥산의 부분입체이성체 둘다인 화합물.The compound of claim 1, which is both diastereomers of 1- (3-ethoxyphenyl) -1- (4-phenylpiperazin-1-yl) -4-methoxy-cyclic hexane. ※ 참고사항 : 최초출원 내용에 의하여 공개하는 것임.※ Note: It is disclosed by the contents of the first application.
KR1019970702989A 1994-11-07 1995-11-07 Substituted benzylamine derivatives; A new class of neuropeptide Y1 specific ligands (CERTAIN SUBSTITUTED BENZYLAMINE DERIVATIVES; A NEW CLASS OF NEUROPEPTIDE Y1 SPECIFIC LIGANDS) KR970707101A (en)

Applications Claiming Priority (7)

Application Number Priority Date Filing Date Title
US33547594A 1994-11-07 1994-11-07
US08/335,475 1994-11-07
US47438395A 1995-06-07 1995-06-07
US48497495A 1995-06-07 1995-06-07
US08/484,974 1995-06-07
US08/474,383 1995-06-07
PCT/US1995/014472 WO1996014307A1 (en) 1994-11-07 1995-11-07 Certain substituted benzylamine derivatives; a new class of neuropeptide y1 specific ligands

Publications (1)

Publication Number Publication Date
KR970707101A true KR970707101A (en) 1997-12-01

Family

ID=27407057

Family Applications (1)

Application Number Title Priority Date Filing Date
KR1019970702989A KR970707101A (en) 1994-11-07 1995-11-07 Substituted benzylamine derivatives; A new class of neuropeptide Y1 specific ligands (CERTAIN SUBSTITUTED BENZYLAMINE DERIVATIVES; A NEW CLASS OF NEUROPEPTIDE Y1 SPECIFIC LIGANDS)

Country Status (13)

Country Link
JP (1) JP3386814B2 (en)
KR (1) KR970707101A (en)
AU (1) AU692977B2 (en)
BR (1) BR9509610A (en)
CA (1) CA2203878C (en)
CZ (1) CZ137297A3 (en)
FI (1) FI971931A0 (en)
HU (1) HUT78089A (en)
NO (1) NO972091L (en)
NZ (1) NZ297211A (en)
PL (1) PL321136A1 (en)
SK (1) SK57097A3 (en)
WO (1) WO1996014307A1 (en)

Families Citing this family (76)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5989920A (en) * 1994-12-02 1999-11-23 Synaptic Pharmaceutical Corporation Methods of modifying feeding behavior compounds useful in such methods and DNA encoding a hypothalmic atypical neuropeptide Y/peptide YY receptor Y5
US5602024A (en) 1994-12-02 1997-02-11 Synaptic Pharmaceutical Corporation DNA encoding a hypothalamic atypical neuropeptide Y/peptide YY receptor (Y5) and uses thereof
CA2261031A1 (en) * 1996-07-23 1998-01-29 Charles A. Blum Certain substituted benzylamine derivatives; a new class of neuropeptide y1 specific ligands
WO1998007420A1 (en) 1996-08-23 1998-02-26 Agouron Acquisition Corp. Neuropeptide-y ligands
FR2754709B1 (en) 1996-10-23 1999-03-05 Sanofi Sa COSMETIC COMPOSITION CONTAINING AN ANTAGONIST OF GAMMA NEUROPEPTIDE RECEPTORS AND ALPHA 2 ANTAGONISTS THAT MAY BE INCORPORATED IN SUCH A COMPOSITION
PA8441701A1 (en) * 1996-11-26 2000-05-24 Pfizer SALTS DIMESYLATE OF THE NEUROPEPTIDE LIGANDS AND
US6245817B1 (en) 1997-02-14 2001-06-12 Bayer Corporation NPY5 receptor antagonists and methods for using same
CA2251368A1 (en) * 1997-02-14 1998-08-20 Bayer Corporation Amide derivatives as selective neuropeptide y receptor antagonists
US6048900A (en) * 1998-02-13 2000-04-11 Bayer Corporation Amide derivatives and methods for using the same as selective neuropeptide Y receptor antagonists
US6713265B1 (en) 1997-06-04 2004-03-30 Synaptic Pharmaceutical Corporation Methods of modifying feeding behavior, compounds useful in such methods, and DNA encoding a hypothalamic atypical neuropeptide Y/peptide YY receptor (Y5)
US5889016A (en) * 1997-06-26 1999-03-30 Bristol-Myers Squibb Company Dihydropyrimidone derivatives as NPY antagonists
DE69830409T2 (en) 1997-08-05 2006-01-26 Pfizer Products Inc., Groton 4-AMINOPYRROLE [3,2-D] PYRIMIDINE AS A NEUROPEPTIDE RECEPTOR ANTAGONIST
PT896822E (en) * 1997-08-05 2003-07-31 Pfizer Prod Inc 4-AMINOPYROLOL (3,2-D) PYRIMIDINES AS ANTAGONISTS OF THE NEUROPEPTIDEO RECEPTOR AND
US6187777B1 (en) 1998-02-06 2001-02-13 Amgen Inc. Compounds and methods which modulate feeding behavior and related diseases
EP1027891B1 (en) 1999-01-27 2004-12-29 Pfizer Products Inc. Neuropeptide y antagonists
AU2935200A (en) 1999-04-30 2000-11-17 Pfizer Products Inc. Compounds for the treatment of obesity
ATE306481T1 (en) 1999-05-12 2005-10-15 Ortho Mcneil Pharm Inc PYRAZOLECARBOXAMIDE USED TO TREAT OBESITY AND OTHER DISEASES
US6177429B1 (en) 1999-06-21 2001-01-23 Bristol-Myers Squibb Company Dihydropyrazine derivatives as NPY antagonists
US6531478B2 (en) 2000-02-24 2003-03-11 Cheryl P. Kordik Amino pyrazole derivatives useful for the treatment of obesity and other disorders
CA2414198A1 (en) 2000-07-06 2002-01-17 Neurogen Corporation Melanin concentrating hormone receptor ligands
US6953801B2 (en) * 2001-05-22 2005-10-11 Neurogen Corporation Melanin concentrating hormone receptor ligands: substituted 1-benzyl-4-aryl piperazine analogues
EP1935885A3 (en) * 2001-05-22 2008-10-15 Neurogen Corporation Melanin concentrating hormone receptor ligands : substituted 1-benzyl-4-aryl piperazine analogues.
DE10213051B4 (en) * 2002-03-23 2013-03-07 Grünenthal GmbH Substituted 4-aminocyclohexanols
US7105526B2 (en) 2002-06-28 2006-09-12 Banyu Pharmaceuticals Co., Ltd. Benzimidazole derivatives
US7772188B2 (en) 2003-01-28 2010-08-10 Ironwood Pharmaceuticals, Inc. Methods and compositions for the treatment of gastrointestinal disorders
JP2007502287A (en) 2003-08-13 2007-02-08 アムジェン インコーポレイテッド Melanin-concentrating hormone receptor antagonist
JP4765627B2 (en) 2003-09-22 2011-09-07 Ｍｓｄ株式会社 Novel piperidine derivatives
EP1734963A4 (en) 2004-04-02 2008-06-18 Merck & Co Inc Method of treating men with metabolic and anthropometric disorders
EP2127676A3 (en) 2004-11-01 2013-09-04 Amylin Pharmaceuticals, LLC Treatment of obesity and related disorders
US7737155B2 (en) 2005-05-17 2010-06-15 Schering Corporation Nitrogen-containing heterocyclic compounds and methods of use thereof
RU2417985C2 (en) 2005-05-30 2011-05-10 Баниу Фармасьютикал Ко., Лтд. Novel piperidine derivatives
JPWO2007018248A1 (en) 2005-08-10 2009-02-19 萬有製薬株式会社 Pyridone compounds
CA2617649A1 (en) 2005-08-11 2007-02-22 Amylin Pharmaceuticals, Inc. Hybrid polypeptides with selectable properties
BRPI0614649A2 (en) 2005-08-11 2011-04-12 Amylin Pharmaceuticals Inc hybrid polypeptides with selectable properties
JPWO2007024004A1 (en) 2005-08-24 2009-03-05 萬有製薬株式会社 Phenylpyridone derivatives
EP1939194A4 (en) 2005-09-07 2010-12-08 Banyu Pharma Co Ltd Bicyclic aromatic substituted pyridone derivative
CA2624030A1 (en) 2005-09-29 2007-04-12 Tianying Jian Acylated spiropiperidine derivatives as melanocortin-4 receptor modulators
CA2625416A1 (en) 2005-10-21 2007-04-26 Novartis Ag Combination of a renin-inhibitor and an anti-dyslipidemic agent and/or an antiobesity agent
EP1944301A4 (en) 2005-10-27 2012-01-04 Msd Kk Novel benzoxathiin derivative
US8158791B2 (en) 2005-11-10 2012-04-17 Msd K.K. Aza-substituted spiro derivatives
EP2946778A1 (en) 2006-09-22 2015-11-25 Merck Sharp & Dohme Corp. Method of treatment using fatty acid synthesis inhibitors
CA2664358A1 (en) 2006-09-28 2008-04-03 Banyu Pharmaceutical Co., Ltd. Diarylketimine derivative
AU2008233662B2 (en) 2007-04-02 2012-08-23 Msd K.K. Indoledione derivative
US8969514B2 (en) 2007-06-04 2015-03-03 Synergy Pharmaceuticals, Inc. Agonists of guanylate cyclase useful for the treatment of hypercholesterolemia, atherosclerosis, coronary heart disease, gallstone, obesity and other cardiovascular diseases
DK2170930T3 (en) 2007-06-04 2012-11-05 Synergy Pharmaceuticals Inc AGONISTS OF GUANYLATCYCLASE USED FOR THE TREATMENT OF GASTROINTESTINAL DISEASES, INFLAMMATION, CANCER AND OTHER DISEASES
JPWO2009110510A1 (en) 2008-03-06 2011-07-14 Ｍｓｄ株式会社 Alkylaminopyridine derivatives
AU2009229860A1 (en) 2008-03-28 2009-10-01 Msd K.K. Diarylmethylamide derivative having antagonistic activity on melanin-concentrating hormone receptor
JP2011522828A (en) 2008-06-04 2011-08-04 シナジー ファーマシューティカルズ インコーポレイテッド Guanylate cyclase agonists useful for the treatment of gastrointestinal disorders, inflammation, cancer, and other disorders
JPWO2009154132A1 (en) 2008-06-19 2011-12-01 Ｍｓｄ株式会社 Spirodiamine-diarylketoxime derivatives
ES2624828T3 (en) 2008-07-16 2017-07-17 Synergy Pharmaceuticals Inc. Guanylate cyclase agonists useful for the treatment of gastrointestinal disorders, inflammation, cancer and others
AU2009277736A1 (en) 2008-07-30 2010-02-04 Banyu Pharmaceutical Co., Ltd. (5-membered)-(5-membered) or (5-membered)-(6-membered) fused ring cycloalkylamine derivative
AU2009307884B2 (en) 2008-10-22 2014-07-31 Merck Sharp & Dohme Corp. Novel cyclic benzimidazole derivatives useful anti-diabetic agents
CA2741644C (en) 2008-10-30 2013-05-07 Merck Sharp & Dohme Corp. Isonicotinamide orexin receptor antagonists
US8329914B2 (en) 2008-10-31 2012-12-11 Merck Sharp & Dohme Corp Cyclic benzimidazole derivatives useful as anti-diabetic agents
WO2010075068A1 (en) 2008-12-16 2010-07-01 Schering Corporation Pyridopyrimidine derivatives and methods of use thereof
US20110243940A1 (en) 2008-12-16 2011-10-06 Schering Corporation Bicyclic pyranone derivatives and methods of use thereof
WO2011106273A1 (en) 2010-02-25 2011-09-01 Merck Sharp & Dohme Corp. Novel cyclic benzimidazole derivatives useful anti-diabetic agents
US9616097B2 (en) 2010-09-15 2017-04-11 Synergy Pharmaceuticals, Inc. Formulations of guanylate cyclase C agonists and methods of use
US8796258B2 (en) 2011-02-25 2014-08-05 Merck Sharp & Dohme Corp. Cyclic azabenzimidazole derivatives useful as anti-diabetic agents
AR088352A1 (en) 2011-10-19 2014-05-28 Merck Sharp & Dohme ANTAGONISTS OF THE RECEIVER OF 2-PIRIDILOXI-4-NITRILE OREXINE
US20140045746A1 (en) 2012-08-02 2014-02-13 Merck Sharp & Dohme Corp. Antidiabetic tricyclic compounds
JP2016516004A (en) 2013-02-22 2016-06-02 メルク・シャープ・アンド・ドーム・コーポレーションＭｅｒｃｋ Ｓｈａｒｐ ＆ Ｄｏｈｍｅ Ｃｏｒｐ． Antidiabetic bicyclic compound
EP2970119B1 (en) 2013-03-14 2021-11-03 Merck Sharp & Dohme Corp. Novel indole derivatives useful as anti-diabetic agents
AU2014235209B2 (en) 2013-03-15 2018-06-14 Bausch Health Ireland Limited Guanylate cyclase receptor agonists combined with other drugs
US9708367B2 (en) 2013-03-15 2017-07-18 Synergy Pharmaceuticals, Inc. Agonists of guanylate cyclase and their uses
KR102272746B1 (en) 2013-06-05 2021-07-08 보슈 헬스 아일랜드 리미티드 Ultra-pure agonists of guanylate cyclase c, method of making and using same
WO2015051496A1 (en) 2013-10-08 2015-04-16 Merck Sharp & Dohme Corp. Antidiabetic tricyclic compounds
DK3186242T3 (en) 2014-08-29 2021-12-20 Tes Pharma S R L ALFA-AMINO-BETA-CARBOXYMUCONSIDE-SEMIALDEHYDE-DECARBOXYLASE INHIBITORS
EP3526199B1 (en) 2016-10-14 2022-04-13 Tes Pharma S.r.l. Inhibitors of alpha-amino-beta-carboxymuconic acid semialdehyde decarboxylase
EP3551176A4 (en) 2016-12-06 2020-06-24 Merck Sharp & Dohme Corp. Antidiabetic heterocyclic compounds
EP3558298A4 (en) 2016-12-20 2020-08-05 Merck Sharp & Dohme Corp. Antidiabetic spirochroman compounds
AR117122A1 (en) 2018-11-20 2021-07-14 Tes Pharma S R L A-AMINO-b-CARBOXIMUCONIC ACID INHIBITORS SEMIALDEHYDE DECARBOXYLASE
TW202045476A (en) 2019-02-13 2020-12-16 美商默沙東藥廠 5-alkyl pyrrolidine orexin receptor agonists
SG11202110742TA (en) 2019-04-02 2021-10-28 Aligos Therapeutics Inc Compounds targeting prmt5
US20230018413A1 (en) 2019-08-08 2023-01-19 Merck Sharp & Dohme Corp. Heteroaryl pyrrolidine and piperidine orexin receptor agonists
CA3189908A1 (en) 2020-08-18 2022-02-24 Stephane L. Bogen Bicycloheptane pyrrolidine orexin receptor agonists

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4845221A (en) * 1988-04-15 1989-07-04 American Home Products Corporation Serotonergic substituted piperazinyl tetralins
DD297968A5 (en) * 1989-04-22 1992-01-30 �����@��������@�K@�����������@�������k�� NEW PIPERAZINE, THEIR PREPARATION AND USE IN PHARMACEUTICAL AGENTS

Also Published As

Publication number Publication date
FI971931A (en) 1997-05-06
CA2203878C (en) 2002-06-25
BR9509610A (en) 1997-10-28
SK57097A3 (en) 1998-10-07
PL321136A1 (en) 1997-11-24
CA2203878A1 (en) 1996-05-17
JP3386814B2 (en) 2003-03-17
AU4231996A (en) 1996-05-31
NZ297211A (en) 1999-01-28
JP2001520625A (en) 2001-10-30
AU692977B2 (en) 1998-06-18
NO972091L (en) 1997-07-02
CZ137297A3 (en) 1998-04-15
HUT78089A (en) 1999-08-30
WO1996014307A1 (en) 1996-05-17
MX9703349A (en) 1997-07-31
FI971931A0 (en) 1997-05-06
NO972091D0 (en) 1997-05-06

Similar Documents

Publication Publication Date Title
KR970707101A (en) Substituted benzylamine derivatives; A new class of neuropeptide Y1 specific ligands (CERTAIN SUBSTITUTED BENZYLAMINE DERIVATIVES; A NEW CLASS OF NEUROPEPTIDE Y1 SPECIFIC LIGANDS)
CA2379640A1 (en) Certain alkylene diamine-substituted heterocycles
KR870007888A (en) Piperidine Derivatives and Pharmaceutical Compositions Containing the Same
NO20032861L (en) Heterory urea neuropeptide Y Y5 receptor antagonists
DE60221098D1 (en) CONDENSED HETEROCYCLIC DERIVATIVES
TR200100137T2 (en) N-substituted aminotetralins as ligands for the neuropeptide Y Y5 receptor useful in the treatment of obesity and other disorders.
DE60129934D1 (en) USE OF PDGF RECEPTOR TYROSINE KINASE INHIBITORS FOR THE TREATMENT OF DIABETIC NEPHROPATHY
ATE213727T1 (en) IN POSITION 3 1,3-DIHYDROINDOL-2-ONE DERIVATIVES SUBSTITUTED BY A NITROGEN GROUP AS VASOPRESSIN AND/OR OCYTOCIN AGONISTS AND/OR ANTAGONISTS
NL970034I2 (en) Trans-6-22- (3- or 4-carbonamido-substituted pyrrol-1-y) alkyl-4-hydroxypyran-2-one as inhibitors of cholesterol synthesis.
DE60327097D1 (en) DIAZINOPYRIMIDINE AND ITS USE AS PROTEIN KINASE INHIBITORS
EP2053041A3 (en) 1,3,5-Trisubstituted 2(1H)-pyridones as AMPA receptor inhibitors useful for the treatment of eg Parkinson's disease
DE69223734D1 (en) Condensed pyrimidine derivatives and their use as angiotensin II antagonists
RU2010154425A (en) NEW URACYL COMPOUND OR ITS SALT POSSESSING INHIBITING ACTIVITY REGARDING HUMAN DESOXIURIDINTRIFOSPHATASE
BR0101527A (en) Thyroid receptor ligands
TR200102138T2 (en) (S) -The potassium salt of omeprazole.
DE69734773D1 (en) NON-PEPTIDIC BOMBESIN RECEPTOR ANTAGONISTS
TR200302077T4 (en) 2- (3,5-Bis-Trifluoromethyl-phenyl) -N-methyl-N- (6-morphonyl-4-yl-4-O-tolyl-pyridin-3-yl) -isobutyramide
DE69602087D1 (en) 1-ARYL-2-ACYLAMINO-ETHAN COMPOUNDS AND THEIR USE AS A NEUROKININE, IN PARTICULAR AS A NEUROKININ-1 ANTAGONIST
TR199801866A1 (en) New piperazine and piperidine compounds
TR199800543A2 (en) Benzyloxy substituted anilylated N-heterocyclic compounds.
KR910011817A (en) Substituted cyclohexenes useful as central nervous system agents
TR200002037T2 (en) E-2- [4- (4-Chloro-1,2-diphenyl-but-1-enyl) phenoxy] ethanol and its pharmaceutical compositions.
KR860001100A (en) Preparation of substituted amide
MX9701363A (en) 2-(piperazinyl-1-carbonylmethyl)-1,4-dihydropyridines as bradykinin antagonists.
DK0882038T3 (en) Substituted N-methyl-N- (4- (piperidin-1-yl) -2- (aryl) butyl) benzamides for the treatment of allergy diseases

Legal Events

Date Code Title Description
A201 Request for examination
E902 Notification of reason for refusal
E601 Decision to refuse application